Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose FOY-305 in Healthy Japanese Men
NCT04451083Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camostat mesilate in coronavirus disease 2019 (COVID-19), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse events up to 10 days, Vital sign up to 10 days and 4 more. Started Jul 2020; status: completed.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04451083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451083.